Short Interest in Eyenovia, Inc. (NASDAQ:EYEN) Grows By 346.2%

Eyenovia, Inc. (NASDAQ:EYEN) was the recipient of a significant increase in short interest during the month of February. As of February 15th, there was short interest totalling 249,400 shares, an increase of 346.2% from the January 31st total of 55,900 shares. Based on an average daily volume of 366,000 shares, the short-interest ratio is currently 0.7 days. Currently, 12.1% of the company’s shares are short sold.

Institutional Trading of Eyenovia

A hedge fund recently raised its stake in Eyenovia stock. Nations Financial Group Inc. IA ADV raised its position in shares of Eyenovia, Inc. (NASDAQ:EYEN) by 78.6% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 90,900 shares of the company’s stock after buying an additional 40,000 shares during the quarter. Nations Financial Group Inc. IA ADV owned about 0.14% of Eyenovia worth $47,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 25.84% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently commented on EYEN. Brookline Capital Management restated a “hold” rating on shares of Eyenovia in a report on Friday, November 15th. LADENBURG THALM/SH SH reiterated a “neutral” rating on shares of Eyenovia in a report on Monday, November 18th. HC Wainwright reiterated a “neutral” rating and set a $2.00 target price on shares of Eyenovia in a report on Thursday, February 6th. Finally, William Blair reiterated a “market perform” rating on shares of Eyenovia in a report on Friday, November 15th.

Eyenovia Stock Down 1.7 %

Eyenovia stock traded down $0.03 during midday trading on Friday, hitting $1.69. 67,503 shares of the company’s stock were exchanged, compared to its average volume of 313,630. The company has a debt-to-equity ratio of 0.58, a quick ratio of 0.55 and a current ratio of 0.74. Eyenovia has a 12 month low of $1.43 and a 12 month high of $205.60. The firm has a 50-day moving average of $4.91 and a two-hundred day moving average of $22.82. The company has a market cap of $2.35 million, a PE ratio of -0.03 and a beta of 1.24.

About Eyenovia

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.